ST. PAUL, Minn.--(BUSINESS WIRE)--EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced today that it expects data from sub-analyses of its VBLOC-RF1 and VBLOC-RF2 studies to be presented at 8:00 AM ART (7:00 AM EDT) on Friday, September 26, 2008 during a general session of the 13th World Congress on Obesity Surgery of the International Federation for the Surgery of Obesity and metabolic disorders (IFSO), being held September 24-27 in Buenos Aires, Argentina.
